Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil[Rm]) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin).

Trial Profile

Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil[Rm]) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Bexarotene
  • Indications Cutaneous T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 29 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 28 Mar 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top